In recent years, more and more studies have shown that miRNAs can affect a variety of biological processes. It is important for disease prevention, treatment, diagnosis, and prognosis to study the relationships between human diseases and miRNAs. However, traditional experimental methods are time-consuming and labour-intensive. Hence, in this paper, a novel neighborhood-based computational model called NBMDA is proposed for predicting potential miRNA-disease associations. Due to the fact that known miRNA-disease associations are very rare and many diseases (or miRNAs) are associated with only one or a few miRNAs (or diseases), in NBMDA, the K-nearest neighbor (KNN) method is utilized as a recommendation algorithm based on known miRNA-disease associations, miRNA functional similarity, disease semantic similarity, and Gaussian interaction profile kernel similarity for miRNAs and diseases to improve its prediction accuracy. And simulation results demonstrate that NBMDA can effectively infer miRNA-disease associations with higher accuracy compared with previous state-of-the-art methods. Moreover, independent case studies of esophageal neoplasms, breast neoplasms and colon neoplasms are further implemented, and as a result, there are 47, 48, and 48 out of the top 50 predicted miRNAs having been successfully confirmed by the previously published literatures, which also indicates that NBMDA can be utilized as a powerful tool to study the relationships between miRNAs and diseases.

1. Introduction

MiRNAs are one kind of small RNAs with the length of about 20–24 nucleotides that can regulate the expression of posttranscriptional genes, and each miRNA may have multiple target genes that can be regulated by multiple miRNAs as well [1–4]. Recently, more and more studies have shown that miRNAs play important roles in many physiological processes of the human body such as cell growth [5], proliferation [6], differentiation [7], immune response [8] embryonic development [5], and so on. In addition, emerging evidences have implied as well that miRNAs can affect the occurrence and development of various tumors by regulating the signaling pathways in which their target genes are involved and play a role similar to oncogenes or tumor suppressor genes [9]. For example, miR-203 can inhibit the formation of esophageal tumors [10], miR-328 is a key oncogene in hepatocellular carcinoma, and its expression level will be significantly upregulated and downregulated in hepatocellular carcinoma tissues [11]. MiR-143 and miR-145 are expressed at low levels in esophageal cancer and gastric cancer, which mean that the downregulation of these two kinds of miRNAs can be considered as a potential biomarker for related tumors [12]. Hence, the exploration of potential relationships between miRNAs and diseases will have important significance for disease prevention, treatment, diagnosis, and prognosis [13–15].

Up to now, many human miRNA-disease association databases such as HMDD [16] and miR2Disease [17] have been established, in which the stored associations are mainly collected from previous biological experiments. And with the rapid growth of known biological information associated with miRNAs and diseases, known miRNA-disease associations are becoming far from meeting the needs of modern
medical researches, since traditional methods of detecting miRNA-disease associations (e.g., PCR [18] and northern blotting [19]) are very time-consuming and labour-intensive. Therefore, in recent years, a large number of computational models have been proposed [20–22]. For instance, based on the assumption that similar miRNAs tend to be related or unrelated with similar diseases [23], Zeng et al. [24] proposed a model to infer potential associations between miRNAs and diseases based on the miRNA similarity, disease similarity, and known miRNA-disease associations. Yu et al. [25] proposed a model called KATZMDA to predict potential miRNA-disease associations by measuring the number and length of paths existing between a pair of miRNA-disease nodes in the miRNA-disease association network. In addition, considering that more and more biological databases have been established by far, it is obvious that the prediction performance would be improved more effectively, if more information collected from more databases are integrated to predict potential miRNA-disease associations. For example, Yu et al. [26] proposed a model called NBCLDA to infer potential associations between lncRNAs and diseases through integrating known miRNA-disease associations, miRNA-lncRNA associations, lncRNA-disease associations, gene-lncRNA associations, gene-disease associations, and gene-miRNA associations. Moreover, for the past few years, with machine learning gradually becoming a hot topic in many fields, some machine learning algorithms have been adopted to predict miRNA-disease associations as well. For instance, Zhang et al. [27] proposed a semisupervised model to infer potential miRNA-disease associations by implementing label propagation algorithms on the miRNA-disease association network. Chen et al. [28] proposed a computational model called SDMMDA based on super-diseases and miRNAs to predict potential miRNA-disease associations, in which as many as possible similar diseases or miRNAs would be clustered into super-diseases or super-miRNAs first, and then the Naive Bayesian scheme was utilized to infer potential associations between miRNAs and diseases. Luo et al. [29] proposed a semisupervised method called KRLSM to identify potential miRNA-disease associations, in which, due to the sparsity of known miRNA-disease associations, different omics data were integrated to improve the prediction accuracy of KRLSM first, and then, the semisupervised classifier of regularized least squares was adopted to calculate the potential probabilities of associations between miRNAs and diseases.

In this paper, different from above mentioned models, a novel neighborhood-based computational model called NBMDA was developed to infer potential miRNA-disease associations, in which, due to the fact that known miRNA-disease associations are quite sparse and there are a variety of diseases (or miRNAs) associating with only one or few miRNAs (or diseases), the K-nearest neighbor (KNN) method would be utilized as a recommendation algorithm to improve the prediction accuracy of NBMDA first, and then, according to two kinds of newly constructed miRNA-disease association networks and the original miRNA-disease association network, the possibilities of potential associations between miRNAs and diseases would be calculated based on the concept of common neighbors. Finally, in order to evaluate the prediction performance of NBMDA, global leave-one-out cross validation (global LOOCV) and 5-fold cross validation (5-fold CV) were implemented simultaneously, and simulation results demonstrated that NBMDA could achieve reliable AUCs of 0.8983/0.8153 and 0.8975 under the global LOOCV and 5-fold CV, respectively, which were higher than several state-of-the-art computational models. In addition, we further implemented the case studies of esophageal neoplasms, breast neoplasms and colon neoplasms on NBMDA, and simulation results illustrated that there were 47, 48, and 48 out of the top 50 predicted miRNAs having been successfully confirmed by the previously published literatures separately, which also demonstrated that NBMDA has good performance in predicting potential miRNA-disease associations. Hence, it is obvious that NBMDA can be further applied to predict both diseases without any known related miRNAs and miRNAs without any known related diseases.

2. Materials and Methods

2.1. Human miRNA-Disease Associations. In order to evaluate the performance of our proposed NBMDA, we use two datasets. The first dataset (denoted as dataset1) was downloaded from the HMDD v2.0 database, which consisted of 5430 experimentally validated human miRNA-disease associations including 495 different miRNAs and 383 different diseases [16]. The second dataset (denoted as dataset2) was downloaded from the miR2Disease database and the HMDD database, which consisted of high-quality experimentally verified microRNA-disease associations [14, 30]. As for the dataset2, after deleting 13 miRNAs that could not be found in the website http://www.cuilab.cn/files/images/cuilab/misim.zip, we finally obtained 250 miRNA-disease associations including 105 different miRNAs and 52 different diseases. And for convenience, we adopted an adjacency matrix A to represent the miRNA-disease associations, in which, for any given disease d(i) and miRNA m(j), if there is a known association between them, then the value of A(i, j) will be set to 1, otherwise A(i, j) will be set to 0. Therefore, the ith row of A denotes the interaction profiles of the disease d(i) with each of these collected miRNAs, and the jth column of A indicates the interaction profiles of the miRNA m(j) with each of these collected diseases. And moreover, the number of diseases and miRNAs collected in this paper will be represented by Nd and Nm, respectively. Hence, based on the adjacency matrix A, we can obtain an original miRNA-disease association network MDA.

2.2. miRNA Functional Similarity. The miRNA functional similarity network can be established based on the assumption that functionally similar miRNAs are always associated with similar diseases [31]. In this section, in order to construct the miRNA functional similarity network, we downloaded the functional similarity scores between miRNAs collected in this study from the website http://www.cuilab.cn/files/images/cuilab/misim.zip and then, for
convenience, we use FS to represent the miRNA functional similarity matrix, in which, the value of FS(i, j) represents the similarity score between the miRNA m(i) and the miRNA m(j).

2.3. Disease Semantic Similarity. The association between diseases can be represented by an directed acyclic graphs (DAGs), in which, a disease D can be described as DAG(D) = (D, T(D), E(D)), where T(D) represents a set of nodes including the D itself and its all ancestor nodes and E(D) is a set consisting of direct edges that connect parent nodes and child nodes in T(D). And moreover, the contribution of a disease d to the semantic value of D can be calculated according to the following formula:

\[
D_{D}(d) = \begin{cases} 
1, & \text{if } d = D, \\
\max\{\Delta, D_{D}(d') \mid d' \in \text{children of } d\}, & \text{if } d \neq D.
\end{cases}
\]

(1)

Additionally, the semantic value of disease D can be obtained as follows:

\[
DV(D) = \sum_{d \in T(D)} D_{D}(d).
\]

(2)

Here, \(\Delta\) is a semantic contribution factor between 0 and 1, which will be set to 0.5 in this paper according to related works [32, 33]. And according to the above Formula (1), it is easy to see that the contribution of the disease D to the semantic value of itself is 1 and the contribution of an ancestor disease d to the semantic value of D gradually decreases with the increasing of the distance between them, which is regulated by \(\Delta\). And additionally, according to Formula (2), it is obvious that the semantic value of D is the sum of the contributions of ancestor diseases to the semantic values of D. In general, based on the assumption that if two diseases share more parts of the DAGs, there should be a higher semantic similarity between them, and the semantic similarity between the disease \(d(i)\) and \(d(j)\) can be obtained according to the following formula:

\[
SS(d(i), d(j)) = \frac{\sum_{d \in T(d(i)) \cap T(d(j))} (D_{d(i)}(t) + D_{d(j)}(t))}{DV(d(i)) + DV(d(j))}.
\]

(3)

Thereafter, according to Formula (3), we can obtain a \(N_d \times N_d\) dimensional disease semantic similarity matrix SS based on these \(N_d\) diseases collected previously.

2.4. Gaussian Interaction Profile Kernel Similarity for miRNAs and Diseases. In this section, based on the hypothesis that similar miRNAs are always related or unrelated to similar diseases, we will adopt the topological information of known miRNA-disease association network to calculate the Gaussian interaction profile kernel similarity for miRNAs. Firstly, let the binary vector IP(m(i)) indicate the \(i^{th}\) column of the adjacency matrix A, then, the Gaussian kernel similarity between the miRNA \(m(i)\) and the miRNA \(m(j)\) can be obtained according to the following formula:

\[
KM(m(i), m(j)) = \exp\left(-\gamma_m \| IP(m(i)) - IP(m(j)) \|^2 \right),
\]

(4)

where \(\gamma_m\) is a parameter used to control the Gaussian kernel bandwidth, and \(\gamma_m\) is defined as follows:

\[
\gamma_m = \frac{1}{1/N_m} \sum_{m} \| IP(m) \|^2
\]

(5)

As shown in Formula (5), there is a new bandwidth parameter \(\gamma_m\), which will be set to 1 according to previous work [34]. Thereafter, a \(N_m \times N_m\) dimensional miRNA Gaussian interaction profile kernel similarity matrix \(KM\) can be obtained based on Formula (4).

Similarly, the Gaussian interaction profile kernel similarity between the disease \(d(i)\) and disease \(d(j)\) can be calculated according to the following formulas:

\[
KD(d(i), d(j)) = \exp\left(-\gamma_d \| IP(d(i)) - IP(d(j)) \|^2 \right),
\]

(6)

\[
\gamma_d = \frac{1}{1/N_d} \sum_{d} \| IP(d) \|^2
\]

(7)

where IP(d(i)) represents the \(i^{th}\) row of the adjacency matrix A, \(\gamma_d\) is a parameter used to control the Gaussian kernel bandwidth, and \(\gamma'_d\) is a bandwidth parameter that will be set to 1 according to previous work [34]. Hence, a \(N_d \times N_d\) dimensional disease Gaussian interaction profile kernel similarity matrix \(KD\) will be obtained based on Formula (6).

2.5. Integrated Similarity for miRNAs and Diseases. In this section, in order to improve the accuracy of our prediction results, we will further construct an integrated miRNA similarity matrix \(S_m\) and an integrated disease similarity matrix \(S_d\) based on these newly obtained matrices such as FS, SS, KM, and KD according to the following formulas separately:

\[
S_m(m(i), m(j)) = \begin{cases} 
KM(m(i), m(j)), & \text{if } FS(i, j) = 0, \\
FS(m(i), m(j)) + KM(m(i), m(j)), & \text{otherwise},
\end{cases}
\]

(8)

\[
S_d(d(i), d(j)) = \begin{cases} 
KD(d(i), d(j)), & \text{if } SS(i, j) = 0, \\
SS(d(i), d(j)) + KD(d(i), d(j)), & \text{otherwise}.
\end{cases}
\]

(9)

2.6. The Prediction Model of NBMDA. For a disease node \(d(i)\) and a miRNA node \(m(j)\) in the miRNA-disease association network, according to the concept of common neighbors given in the previous literature [35], considering the computational complexity, we define the common neighbors (CNs) between \(d(i)\) and \(m(j)\) as the nodes that are involved in all possible quadrangular closure between \(d(i)\) and \(m(j)\) in the miRNA-disease association network. Obviously, the
more CNs between two seed nodes such as \(d(i)\) and \(m(j)\), the greater the possibility that these two seed nodes are associated with each other will be. In addition, according to LCP-theory (i.e., the theory of local community paradigm) [35, 36], it is easy to know that the information content related with the common neighbor nodes should be complemented with the topological information emerging from their interactions. Hence, in this section, we introduced LCLs to indicate the number of links that exist between CNs in the miRNA-disease association network. While searching for CNs between two seed nodes in the miRNA-disease association network, we will temporarily remove the connection between these two seed nodes if there is a connection between them. Based on the above LCP-theory, we proposed a novel neighborhood-based computational model called NBMDA for potential miRNA-disease association prediction. In the model of NBMDA, firstly, an integrated miRNA similarity and an integrated disease similarity will be obtained based on the miRNA functional similarity, the disease semantic similarity, and the Gaussian interaction profile kernel similarity for miRNAs and diseases, respectively. And then, considering that known miRNA-disease associations are quite sparse and many diseases (or miRNAs) are associated with only one or a few miRNAs (or diseases), we adopted KNN as a recommendation algorithm to improve the prediction accuracy of NBMDA. Its main idea is to obtain \(K\) different diseases that are most similar to a randomly given disease \(d(i)\) based on the integrated disease similarity, if most of these \(K\) diseases are associated with a same miRNA \(m(k)\), then it is obvious that we can assume that disease \(d(i)\) is associated with the miRNA \(m(k)\), and therefore, we can construct a new miRNA-disease association network SDA. In a similar way, we can as well obtain \(K\) different miRNAs that are most similar to a randomly given miRNA \(m(j)\) based on the integrated miRNA similarity, if most of these \(K\) miRNAs are associated with a same disease \(d(k)\), then we can assume that miRNA \(m(j)\) is associated with the disease \(d(k)\), and therefore, we can further construct another new miRNA-disease association network SMA. Furthermore, considering the selection of the value of \(K\) while adopting KNN, we tried different values of \(K\) from 1 to 5 and found that the best experimental results can be achieved by NBMDA when \(K\) is set to 3. And as a result, an example is shown in Figure 1, in which, in order to predict the potential association between \(D_1\) and \(M_1\), in SDA, based on the integrated disease similarity, we can obtain three diseases \(D_2, D_3,\) and \(D_6\) that are the most similar to \(D_1\), and then, we can obtain a new disease-miRNA association matrix based on 3NN. Additionally, in SMA, while calculating the association probability between the seed nodes \(D_1\) and \(M_1\), we will temporarily remove the connection between them.

According to above descriptions, as illustrated in Figure 1, based on the concept of common neighbors and these newly constructed networks such as SDA and SMA and the original miRNA-disease association network MDA, for any given disease \(d(i)\) and miRNA \(m(j)\), the possibility of potential association between them can be calculated as follows:

\[
\text{score}(i, j) = \frac{\text{CJC}_{\text{MDA}}(i, j) \times \text{CJC}_{\text{SDA}}(i, j) \times \text{CJC}_{\text{SMA}}(i, j)}{3} \\
\text{CJC}_{\text{X}}(i, j) = \frac{\text{CN}_{\text{X}}(X, d(i), m(j)) \times \{\text{LCL}_{\text{X}}(X, d(i), m(j))\}}{[N(X, d(i)) \cup N(X, m(j))]},
\]

where \(X \in \{\text{MDA, SDA, SMA}\}\), \(\text{CN}_{\text{X}}(X, d(i), m(j))\) represents the number of common neighbors between the disease \(d(i)\) and the miRNA \(m(j)\) in the network \(X\), \(\text{LCL}_{\text{X}}(X, d(i), m(j))\) represents the number of connections existing among the common neighbors between the disease \(d(i)\) and the miRNA \(m(j)\) in the network \(X\), \(N(X, d(i))\) represents the degree of disease \(d(i)\) in the network \(X\), and \(N(X, m(j))\) represents the degree of miRNA \(m(j)\) in the network \(X\).

3. Results

3.1. Performance Evaluation. To evaluate the predictive performance of NBMDA, we performed LOOCV and 5-fold CV on dataset1 and LOOCV on dataset2 separately. And during simulation, under the global LOOCV framework, each known miRNA-disease association is alternately utilized as a test sample and other known miRNA-disease associations are considered as a training set. Hence, the process needs to be repeated 5430/250 times in total, and during each round of iteration, the predicted score of test sample was ranked with predicted score of all the miRNA-disease pairs without any known association evidences, and if its ranking is above a given cutoff, it will be considered as a successful prediction made by NBMDA. As for 5-fold CV, all known associations are randomly divided into five equal sized and uncrossed subsets, and among them, four subsets are used for model training and the other for model testing. In order to reduce the impact of data partitioning on the prediction results, we repeated 5-fold CV for 100 times. Finally, the receiver operating characteristic (ROC) curves which show the relationship between the true positive rate (TPR, sensitivity) and false positive rate (FPR, 1-specificity) were drawn for further model evaluation and comparison based on TPR and FPR which were obtained by different thresholds. Here, \(TPR = TP/(TP + FN)\) represents the percentage of positive samples identified by the prediction model to all positive samples, and \(FPR = FP/(FP + TN)\) indicates the proportion that the prediction model incorrectly considers the negative samples of the positive class to account for all negative samples. Moreover, the areas under ROC curves (AUCs) are calculated as a standard for model performance evaluation. The larger the value of AUC is, the better the prediction performance of the model will be.

To further evaluate the predictive performance of NBMDA, we compared NBMDA with two state-of-the-art computational methods such as WBSMDA [37] and RLSMDA [38] in terms of global LOOCV and 5-fold CV as well, and the simulation result is shown in the above Figure 2. It is easy to see that NBMDA, RLSMDA, and WBSMDA can achieve reliable AUCs of 0.8983/0.8153, 0.8501/0.7702, and 0.7740/0.7142, respectively. And moreover,
in the 5-fold CV, simulation results show that NBMDA can achieve reliable average AUCs of 0.8975 ± 0.0008. Hence, it is obvious that NBMDA can achieve much better AUCs than these two kinds of state-of-the-art computational methods in terms of both global LOOCV and 5-fold CV, which also demonstrate that NBMDA has reliable performance in potential miRNA-disease association prediction and can improve the predictive performance of previous state-of-the-art computational models effectively.

3.2. Case Studies. More and more evidences have shown that miRNAs play an important role in the occurrence and development of human diseases [39, 40]; therefore, effective
prediction models are important for discovering potential miRNA-disease associations and medical researches. In order to further evaluate the predictive performance of NBMDA, we implemented the case studies of esophageal neoplasms, breast neoplasms and colon neoplasms on dataset1. The 5430 miRNA-disease associations downloaded from HMDD v2.0 were used as a training sample for model learning, and 50 predicted miRNAs with the strongest association with esophageal neoplasms, breast neoplasms and colon neoplasms will be ranked according to their scores respectively and then verified by the records stored in the dbDEMC and miR2Disease databases. What needs to be emphasized is that only miRNA-disease pairs which have not been included in the HMDD v2.0 database would be considered as validation candidates.

Among these kinds of diseases, esophageal neoplasms (EN) is a cancer with a high incidence and is the eighth most common cancer in the world and the sixth leading cause of cancer death in humans [41]. Esophageal cancer is a common digestive tract cancer, and around 300 thousand people worldwide die from the disease every year. Related data show that the survival rate of patients with esophageal cancer has increased from 15% to 25% in the last five years [42]. If treatment can be performed early in this disease, the survival rate can reach 90%. Therefore, the study of potential biomarkers associated with disease is important for the treatment of related diseases. Recently, related studies have achieved some interesting results. For example, mir-21, miR-143, miR-203, miR-205, and miR-221 were found to be expressed at high levels in esophageal cancer tissues [43]. MiR-375 was found to be expressed at low levels in EN cells, and downregulation of miR-375 can be used as a biomarker for predicting esophageal tumors [44]. In this section, in order to identify miRNAs that are potentially associated with EN, we conducted a case study of EN based on NBMDA, and the simulation results show that 47 out of top 50 potential associated miRNAs are validated by dbDEMC and miR2Disease (Table 1). And moreover, related literatures show that miR-17 (ranking 1st in our prediction list) promotes the growth of EN cells and regulates disorders in a variety of cancers [45, 46]. Mir-125b (ranking 2nd in our prediction list) is expressed at low level in EN cells and can promote the differentiation of EN cells [47, 48].

Breast neoplasms (BN) is a common disease, and breast cancer is the most common malignant tumor in women, accounting for 25% [49, 50]. In recent years, the incidence of breast cancer is on the rise and the mortality rate is decreasing. But in developing countries, the survival rate of patients is still low [51]. In the United States, an average of 185,000 women suffer from breast cancer each year and 44,000 people die from this disease. Therefore, a large number of studies are devoted to the treatment of the disease, and identifying potential miRNAs associated with the disease is an important means. Up to now, a lot of achievements have been made in this direction. For example, miRNA-10b was found to be highly expressed in metastatic breast cancer cells and has a positive regulatory effect on cell migration and invasion [52]. Mir-125b, mir-145, mir-21, and mir-155 are significantly dysregulated in breast cancer patients and can be used as potential biomarkers for early detection of BN [52]. MiR-200c-141, miR-200b-200a-429, and miR-183-96-182 are downregulated in human breast cancer stem cells [53]. Hence, in this section, in order to identify miRNAs that are potentially associated with BN, we conducted a case study of breast neoplasms based on NBMDA. And simulation results show that 10 out of top 10 and 48 out of top 50 predicted miRNAs are validated by dbDEMC and miR2Disease (Table 2). In addition, previously published literatures show that mir-142 (ranking 1st in our prediction list) can regulate the tumorigenicity of human breast cancer stem cells [54]. The expression of miR-150 (ranking 2nd in our prediction list) can

**Table 1: The top 50 predicted miRNAs associated with EN obtained by implementing our model NBMDA.**

| miRNA     | Evidence | miRNA     | Evidence |
|-----------|----------|-----------|----------|
| hsa-mir-17| dbdemc   | hsa-mir-195| dbdemc   |
| hsa-mir-125b| dbdemc | hsa-mir-124| dbdemc   |
| hsa-mir-16 | dbdemc   | hsa-mir-7 | dbdemc   |
| hsa-mir-18a| dbdemc   | hsa-mir-93| dbdemc   |
| hsa-mir-29a| dbdemc   | hsa-let-7i| dbdemc   |
| hsa-mir-1  | dbdemc   | hsa-mir-429| dbdemc   |
| hsa-mir-19b| Unconfirmed | hsa-mir-106b| dbdemc   |
| hsa-mir-221| dbdemc   | hsa-mir-125a| dbdemc   |
| hsa-mir-200b| dbdemc | hsa-mir-23a| dbdemc   |
| hsa-mir-142| dbdemc   | hsa-mir-497| dbdemc   |
| hsa-mir-10b| dbdemc   | hsa-mir-106a| dbdemc   |
| hsa-mir-29b| dbdemc   | hsa-mir-30c| dbdemc   |
| hsa-let-7e | dbdemc   | hsa-mir-151a| dbdemc   |
| hsa-let-7d | dbdemc   | hsa-mir-224| dbdemc   |
| hsa-mir-146b| dbdemc | hsa-mir-127| dbdemc   |
| hsa-mir-218| dbdemc   | hsa-mir-24 | dbdemc   |
| hsa-mir-222| dbdemc   | hsa-mir-199b| dbdemc   |
| hsa-mir-133b| dbdemc | hsa-mir-107| dbdemc; miR2Disease |
| hsa-mir-182| dbdemc   | hsa-mir-135a| dbdemc   |
| hsa-mir-181a| dbdemc | hsa-mir-10a| Unconfirmed |
| hsa-mir-9 | dbdemc   | hsa-mir-96 | dbdemc   |
| hsa-mir-181b| dbdemc | hsa-mir-103a| dbdemc   |
| hsa-mir-30a| dbdemc   | hsa-mir-18b| dbdemc   |
| hsa-let-7g | dbdemc   | hsa-mir-378a| dbdemc   |
| hsa-let-7f | Unconfirmed | hsa-mir-302b| dbdemc   |
significantly inhibit the migration and invasion of breast cancer cells in vitro [55].

Colon neoplasms (CN) are common malignant tumors in the gastrointestinal tract; the incidence rate is second only to gastric cancer and esophageal cancer. It is the most common part of colorectal cancer, accounting for about 60%. In recent years, the number of CN patients is increasing year by year. It is reported that the number of patients with colorectal cancer increases globally by 930,000 per year. However, colon neoplasms is the most easily self-screening conditions, if detected early can be cured. Therefore, detecting potential biomarkers of colon tumors has great significance for the treatment of the disease. Related studies have identified several miRNAs associated with CN. For example, miR-143 and miR-145 are expressed at low levels in CN cells [56]. The serum miRNA-21 content in CN patients is abnormally reduced. Therefore, miRNA-21 may be a potential molecular mechanism regulating angiogenesis in CN [57]. These findings provide a theoretical basis for clinical treatment of CN. Hence, in this section, in order to further discover miRNAs associated with colon tumors, we conducted a case study of colon neoplasms based on NBMDA. And simulation results show that 48 out of top 50 predicted miRNAs are successfully validated by dbDEMC and miR2Disease (Table 3). In addition, some previous experimental literatures show that miR-20a (ranking 1st in our prediction list) upregulates in colon neoplasms cells; its downregulation is also considered to be a biomarker for CN [58]. MiR-18a (ranking 2nd in our prediction list) inhibits the progression of colon cancer and induces apoptosis in colon cancer cells [59]. The miR-143 (ranking 3rd in our prediction list) is downregulated in various cancers including colon cancer, and its antitumor activity can inhibit the proliferation and migration of cancer cells [60].

### Table 2: The top 50 predicted miRNAs associated with BN obtained by implementing our model NBMDA.

| miRNA     | Evidence | miRNA     | Evidence |
|-----------|----------|-----------|----------|
| hsa-mir-142 | dbDEMC  | hsa-mir-615 | dbDEMC  |
| hsa-mir-150 | dbDEMC  | hsa-mir-449a | dbDEMC |
| hsa-mir-106a | dbDEMC  | hsa-mir-1273c | Unconfirmed |
| hsa-mir-99a | dbDEMC  | hsa-mir-130b | dbDEMC |
| hsa-mir-98  | miR2Disease | hsa-mir-381 | dbDEMC  |
| hsa-mir-378a | dbDEMC  | hsa-mir-542   | dbDEMC  |
| hsa-mir-130a | dbDEMC  | hsa-mir-337   | dbDEMC  |
| hsa-mir-138  | dbDEMC  | hsa-mir-371a  | dbDEMC  |
| hsa-mir-15b  | dbDEMC  | hsa-mir-95    | dbDEMC  |
| hsa-mir-532  | dbDEMC  | hsa-mir-181c  | dbDEMC  |
| hsa-mir-181d | dbDEMC; miR2Disease | hsa-mir-449b | dbDEMC |
| hsa-mir-192  | dbDEMC  | hsa-mir-30e   | dbDEMC  |
| hsa-mir-198  | dbDEMC  | hsa-mir-637   | dbDEMC  |
| hsa-mir-186  | dbDEMC  | hsa-mir-519b  | dbDEMC  |
| hsa-mir-185  | dbDEMC  | hsa-mir-330   | dbDEMC  |
| hsa-mir-212  | dbDEMC  | hsa-mir-208b  | dbDEMC  |
| hsa-mir-196b | dbDEMC  | hsa-mir-372   | dbDEMC  |
| hsa-mir-527  | dbDEMC  | hsa-mir-602   | dbDEMC  |
| hsa-mir-526b | dbDEMC  | hsa-mir-370   | dbDEMC  |
| hsa-mir-99b  | dbDEMC | hsa-mir-211   | miR2Disease |
| hsa-mir-1280 | Unconfirmed | hsa-mir-32    | dbDEMC  |
| hsa-mir-574  | dbDEMC  | hsa-mir-514a  | dbDEMC  |
| hsa-mir-548b | dbDEMC  | hsa-mir-362   | dbDEMC  |
| hsa-let-92b  | dbDEMC  | hsa-mir-652   | dbDEMC  |
| hsa-let-432  | dbDEMC  | hsa-mir-873   | dbDEMC  |

### Table 3: The top 50 predicted miRNAs associated with CN obtained by implementing our model NBMDA.

| miRNA     | Evidence | miRNA     | Evidence |
|-----------|----------|-----------|----------|
| hsa-mir-20a | dbDEMC; miR2Disease | hsa-mir-200a | dbDEMC |
| hsa-mir-18a | dbDEMC; miR2Disease | hsa-mir-15a  | dbDEMC  |
| hsa-mir-143 | miR2Disease | hsa-mir-15a  | dbDEMC  |
| hsa-mir-19b  | dbDEMC; miR2Disease | hsa-mir-181a | miR2Disease |
| hsa-mir-92a  | dbDEMC; miR2Disease | hsa-mir-181b | dbDEMC; miR2Disease |
| hsa-mir-155  | dbDEMC | hsa-mir-27a  | miR2Disease |
| hsa-mir-125b | dbDEMC | hsa-mir-133b | dbDEMC; miR2Disease |
| hsa-let-7a   | Unconfirmed | hsa-let-7b   | dbDEMC  |
| hsa-mir-19a  | miR2Disease | hsa-mir-142  | dbDEMC  |
| hsa-mir-16   | dbDEMC; miR2Disease | hsa-mir-210  | dbDEMC  |
| hsa-mir-200c | Unconfirmed | hsa-mir-203  | dbDEMC; miR2Disease |
| hsa-mir-34a  | dbDEMC; miR2Disease | hsa-mir-34c   | miR2Disease |
| hsa-let-31   | miR2Disease | hsa-mir-100  | dbDEMC  |
| hsa-let-146a | dbDEMC; miR2Disease | hsa-let-7    | dbDEMC  |
| hsa-mir-10b  | dbDEMC | hsa-mir-101  | dbDEMC  |
| hsa-mir-200b | dbDEMC; miR2Disease | hsa-mir-106b | dbDEMC; miR2Disease |
| hsa-mir-21   | dbDEMC | hsa-mir-183  | miR2Disease |
| hsa-mir-218  | dbDEMC; miR2Disease | hsa-mir-7d    | dbDEMC  |
| hsa-mir-221  | dbDEMC | hsa-mir-146b | dbDEMC  |
| hsa-mir-182  | dbDEMC; miR2Disease | hsa-mir-222  | dbDEMC  |
| hsa-mir-205  | miR2Disease | hsa-let-7e   | dbDEMC  |
| hsa-mir-29a  | dbDEMC | hsa-let-7c   | dbDEMC  |
| hsa-mir-1     | dbDEMC; miR2Disease | hsa-mir-375  | dbDEMC  |
| hsa-let-9    | dbDEMC; miR2Disease | hsa-mir-34b   | dbDEMC; miR2Disease |
| hsa-let-29b  | dbDEMC; miR2Disease | hsa-mir-141   | dbDEMC  |
| hsa-mir-20a  | dbDEMC; miR2Disease | hsa-mir-150   | dbDEMC  |

### 4. Discussion

In this paper, a neighborhood-based computational model called NBMDA is proposed for potential miRNA-disease...
association prediction. In NBMDA, an integrated disease similarity network and an integrated miRNA similarity network will be constructed first based on the disease semantic similarity, the miRNA functional similarity, and the Gaussian interaction profile kernel similarity for diseases and miRNAs. And then, based on the two integrated similarity networks, the KNN method will be adopted as a recommendation algorithm to solve the problem that known miRNA-disease associations are very sparse. Finally, based on the concept of common neighbors, the possibilities of potential associations between miRNAs and diseases can be calculated based on these two newly constructed miRNA-disease association networks and the original miRNA-disease association network. And experimental results show that NBMDA can achieve reliable AUCs of 0.8983/0.8153 and 0.8975 in the frameworks of global LOOCV and 5-fold CV, respectively, which are much better than the AUCs achieved by state-of-the-art prediction models such as WBMSDA and RLSMDA. Moreover, by implementing NBMDA in case studies of esophageal neoplasms, breast neoplasms, and colon neoplasms, there are 47, 48, and 48 out of the top 50 predicted miRNAs having been validated by relevant databases or related literatures separately, which further demonstrate that NBMDA can achieve excellent predictive performance.

The advantages of NBMDA lie in the following aspects: firstly, an integrated disease similarity and an integrated miRNA similarity were obtained by combining the disease semantic similarity, the miRNA functional similarity, and the Gaussian interaction profile kernel similarity for diseases and miRNAs separately, which solved the problem of the sparseness of the similarity matrix to some extent. In addition, the KNN method was adopted as a recommendation algorithm to solve the problem of scarcity of known miRNA-disease associations and the problem that the number of common neighbors between two seed nodes in the association network may be 0.

Of course, there will be some limitations in NBMDA that need to be improved in the future works. Firstly, the known miRNA-disease associations obtained from the database are very limited, which accounts for only 2.9% of all possible associations. Secondly, the newly proposed method to solve the problem of the sparseness of the miRNA functional similarity matrix and the disease semantic similarity matrix is relatively simple, and a more effective and reasonable measure of miRNA and disease similarity will be helpful to further improve the prediction performance of NBMDA.

5. Conclusions

A growing number of studies have shown that miRNAs are associated with a variety of complex human diseases. Therefore, the detection of potential miRNA-disease associations has great significance for the treatment of the disease and human health. In this paper, we proposed a computational model called NBMDA to discover potential miRNA-disease associations. And in order to evaluate the prediction performance of NBMDA, we compared it with some existing state-of-the-art prediction models in terms of LOOCV and 5-fold CV, respectively, and both the simulation results and case studies indicate that NBMDA can effectively predict potential miRNA-disease associations. Therefore, NBMDA can be a powerful tool for identifying potential biomarkers of diseases.

Data Availability

Readers can download the dataset used in this article from http://www.cuilab.cn/hmdd and http://www.mir2disease.org/.

Conflicts of Interest

The authors declare no conflicts of interest on this manuscript.

Acknowledgments

The project is partly sponsored by the National Natural Science Foundation of China (Nos. 61873221 and 61702180), the Natural Science Foundation of Hunan Province (Nos. 2018JJ4058 and 2017JJ5036), and the CERNET Next Generation Internet Technology Innovation Project (Nos. NGII20160305 and NGII20170109).

Supplementary Materials

Experimentally verified microRNA-disease associations. Each line represents an association between a microRNA and a disease. (Supplementary Materials)

References

[1] D. P. Bartel, “MicroRNAs: genomics, biogenesis, mechanism, and function,” Cell, vol. 116, no. 2, pp. 281–297, 2004.
[2] S. K. Wyman, E. C. Knouf, R. K. Parkin et al., “Post-transcriptional generation of miRNA variants by multiple nucleotidyl transferases contributes to miRNA transcriptome complexity,” Genome Research, vol. 21, no. 9, pp. 1450–1461, 2011.
[3] V. Ambros, “The functions of animal microRNAs,” Nature, vol. 431, no. 7006, pp. 350–355, 2004.
[4] D. Sun, A. Li, H. Feng, and M. Wang, “NTSMDA: prediction of miRNA-disease associations by integrating network topological similarity,” Molecular Biosystems, vol. 12, no. 7, pp. 2224–2232, 2016.
[5] V. Ambros, “MicroRNA pathways in flies and worms,” Cell, vol. 113, no. 6, pp. 673–676, 2003.
[6] A. M. Cheng et al., “Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis,” Nucleic Acids Research, vol. 33, no. 4, pp. 1290–1297, 2005.
[7] C.-Z. Chen et al., “MicroRNAs modulate hematopoietic lineage differentiation,” Science, vol. 303, no. 5654, pp. 83–86, 2004.
[8] K. D. Taganov, M. P. Boldin, K.-J. Chang, and D. Baltimore, “NF-B-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses,” in Proceedings of the National Academy of Sciences, vol. 103, 33, pp. 12481–12486, 2006.
Computational and Mathematical Methods in Medicine

[9] R. Chu, G. Mo, Z. Duan et al., “miRNAs affect the development of hepatocellular carcinoma via dysregulation of their biogenesis and expression,” Cell Communication and Signaling, vol. 12, no. 1, p. 45, 2014.

[10] Y. Yang et al., “MicroRNA-203 inhibits cell proliferation by repressing ALP63 expression in human esophageal squamous cell carcinoma,” BMC Cancer, vol. 11, no. 1, p. 57, 2011.

[11] X. Luo et al., “MicroRNA-328 enhances cellular motility through post-transcriptional regulation of PTEN in human hepatocellular carcinoma,” Oncotargets and Therapy, vol. 8, pp. 3159–3167, 2015.

[12] T. Takagi, A. Iso, Y. Nakagawa, T. Naoe, N. Tanigawa, and Y. Akao, “Decreased expression of microRNA-143 and -145 in human gastric cancers,” Oncology, vol. 77, no. 1, pp. 12–21, 2009.

[13] J. Weidhaas, “Using microRNAs to understand cancer biology,” Lancet Oncology, vol. 11, no. 2, pp. 106–107, 2010.

[14] Q. Jiang, Y. Hao, G. Wang et al., “Prioritization of disease microRNAs through a human phenome-microRNAome network,” BMC Systems Biology, vol. 4, no. 1, p. 2, 2010.

[15] G. A. Calin and C. M. Croce, “MicroRNA signatures in human cancers,” Nature Reviews Cancer, vol. 6, no. 11, pp. 857–866, 2006.

[16] Y. Li, C. Qiu, J. Tu et al., “HMDD v2.0: a database for experimentally supported human microRNA and disease associations,” Nucleic Acids Research, vol. 42, no. 1, pp. 1070–1074, 2013.

[17] Q. Jiang, Y. Wang, Y. Hao et al., “miR2Disease: a manually curated database for microRNA deregulation in human disease,” Nucleic Acids Research, vol. 37, no. 1, pp. 98–104, 2009.

[18] Y. Chen, J. A. Gelfond, L. M. McManus, and P. K. Shireman, “Reproducibility of quantitative RT-PCR array in miRNA expression profiling and comparison with microarray analysis,” BMC Genomics, vol. 10, no. 1, p. 407, 2009.

[19] Z. Havelda, v. Vrallyay, A. Vlczi, and J. Burgyn, “Plant virus infection-induced persistent host gene downregulation in systematically infected leaves,” Plant Journal, vol. 55, no. 2, pp. 278–288, 2008.

[20] I. Alvarez-Garcia and E. A. Miska, “MicroRNA functions in animal development and human disease,” Development, vol. 132, no. 21, pp. 4653–4662, 2005.

[21] H. Zhao, L. Kuang, L. Wang et al., “Prediction of microRNA-disease associations based on distance correlation set,” BMC Bioinformatics, vol. 19, no. 1, p. 141, 2018.

[22] J. Xu, C.-X. Li, Y.-S. Li et al., “MiRNA-miRNA synergistic network: construction via co-regulating functional modules and disease miRNA topological features,” Nucleic Acids Research, vol. 39, no. 3, pp. 825–836, 2010.

[23] M. Lu, Q. Zhang, M. Deng et al., “An analysis of human microRNA and disease associations,” PLoS One, vol. 3, no. 10, Article ID e3420, 2008.

[24] X. Zeng, L. Liu, L. Lü, and Q. Zou, “Prediction of potential disease-associated microRNAs using structural perturbation method,” Bioinformatics, vol. 34, no. 14, pp. 2425–2432, 2018.

[25] Q. Yu, H. Zhang, C. Liang, and X. Dong, “KATZMDA: prediction of microRNA-disease associations based on KATZ model,” IEEE Access, vol. 6, pp. 3943–3950, 2018.

[26] J. Yu, P. Ping, L. Wang, L. Kuang, X. Li, and Z. Wu, “A novel probability model for LncRNA-disease association prediction based on the naive bayesian classifier,” Genes, vol. 9, no. 7, p. 345, 2018.

[27] X. Zhang, J. Yin, and X. Zhang, “A semi-supervised learning algorithm for predicting four types MiRNA-disease associations by mutual information in a heterogeneous network,” Genes, vol. 9, no. 3, p. 139, 2018.

[28] X. Chen, Z.-C. Jiang, D. Xie et al., “A novel computational model based on super-disease and microRNA for potential microRNA-disease association prediction,” Molecular Systems, vol. 13, no. 6, pp. 1202–1212, 2017.

[29] J. Luo, Q. Xiao, C. Liang, and P. Ding, “Predicting microRNA-disease associations using kmeroncorke regularized least squares based on heterogeneous omics data,” IEEE Access, vol. 5, no. 99, pp. 2503–2513, 2017.

[30] H. Chen and Z. Zhang, “Similarity-based methods for potential human microRNA-disease association prediction,” BMC Medical Genomics, vol. 6, no. 1, p. 12, 2013.
[45] X.-L. Xu, Y.-H. Jiang, J.-G. Feng, D. Su, P.-C. Chen, and W.-M. Mao, "MicroRNA-17, microRNA-18a, and microRNA-19a are prognostic indicators in esophageal squamous cell carcinoma," *Annals of Thoracic Surgery*, vol. 97, no. 3, pp. 1037–1045, 2014.

[46] L. Zhang, J. Huang, N. Yang et al., "microRNAs exhibit high frequency genomic alterations in human cancer," *Proceedings of the National Academy of Sciences*, vol. 103, no. 24, pp. 9136–9141, 2006.

[47] T. Kan and S. J. Meltzer, "MicroRNAs in Barrett's esophagus and esophageal adenocarcinoma," *Current Opinion in Pharmacology*, vol. 9, no. 6, pp. 727–732, 2009.

[48] R.-J. Lin, D.-W. Xiao, L.-D. Liao et al., "MiR-142-3p as a potential prognostic biomarker for esophageal squamous cell carcinoma," *Journal of Surgical Oncology*, vol. 105, no. 2, pp. 175–182, 2011.

[49] A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, "Global cancer statistics," *CA: A Cancer Journal for Clinicians*, vol. 61, no. 2, pp. 69–90, 2011.

[50] C. E. DeSantis, R. L. Siegel, A. G. Sauer et al., "Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities," *CA: A Cancer Journal for Clinicians*, vol. 66, no. 4, pp. 290–308, 2016.

[51] L. Ma, J. Teruya-Feldstein, and R. A. Weinberg, "Tumour invasion and metastasis initiated by microRNA-10b in breast cancer," *Nature*, vol. 449, pp. 682–688, 2007.

[52] M. V. Iorio, M. Ferracin, C.-G. Liu et al., "MicroRNA gene expression deregulation in human breast cancer," *Cancer Research*, vol. 65, no. 16, pp. 7065–7070, 2005.

[53] Y. Shimono, M. Zabala, R. W. Cho et al., "Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells," *Journal of End-to-End-Testing*, vol. 138, no. 3, pp. 592–603, 2009.

[54] T. Isobe, S. Hisamori, D. J. Hogan et al., "miR-142 regulates the tumorigenicity of human breast cancer stem cells through the canonical WNT signaling pathway," *eLife*, vol. 3, 2014.

[55] N. D'Amato, H. Gu, M. Lee et al., "A functional role for miR-150 in breast cancer," *Cancer Research*, vol. 72, no. 24, 2012.

[56] H. Zhu, U. Dougherty, V. Robinson et al., "EGFR signals downregulate tumor suppressors miR-143 and miR-145 in Western diet-promoted murine colon cancer: role of G1 regulators," *Molecular Cancer Research*, vol. 9, no. 7, pp. 960–975, 2011.

[57] T. T. Liu, "Serum content detection of miRNA-21 in colon cancer patients and its correlation with VEGF level," *Journal of Hainan Medical University*, vol. 101, no. 11, pp. 1384–1395, 2014.

[58] K. Motoyama et al., "Over- and under-expressed microRNAs in human colorectal cancer," *International Journal of Oncology*, vol. 34, no. 4, pp. 1069–1075, 2009.

[59] W. P. Tsang and T. T. Kwok, "The miR-18a microRNA functions as a potential tumor suppressor by targeting on K-Ras," *Carcinogenesis*, vol. 30, no. 6, pp. 953–959, 2009.

[60] K. M. Bauer and A. B. Hummon, "Effects of the miR-143/-145 MicroRNA cluster on the colon cancer proteome and transcriptome," *Journal of Proteome Research*, vol. 11, no. 9, pp. 4744–4754, 2012.